SCHEMBL2128341

SCHEMBL2128341

COC(=O)c1ccccc1C=Cc1cc(-c2ccc[nH]c2=O)cc(C(C)(C)C)c1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.62
ROCK2 O75116 1/20 0.36
CSF1R P07333 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CDK5 Q00535 1/20 0.36
ROCK1 Q13464 1/20 0.36
SLK Q9H2G2 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
TNFRSF1A P19438 1/20 0.35
BACE1 P56817 1/20 0.35
CHEK1 O14757 1/20 0.34
SLC6A3 Q01959 4/20 0.34
SLC6A4 P31645 3/20 0.34
SLC6A2 P23975 1/20 0.34
ABL1 P00519 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542678 1.00 CYP3A4 (0.62) CYP3A4ROCK2CSF1RKDRFLT3
SCHEMBL1542955 0.91 CYP3A4 (0.61) CYP3A4TNFRSF1ACHEK1KDM4EEGFR
SCHEMBL2128073 0.91 CYP3A4 (0.61) CYP3A4TNFRSF1ACHEK1KDM4EEGFR
SCHEMBL1543043 0.91 CYP3A4 (0.61) CYP3A4TNFRSF1ACHEK1ABL1EGFR
SCHEMBL1543045 0.91 CYP3A4 (0.61) CYP3A4TNFRSF1ACHEK1ABL1EGFR
SCHEMBL1764952 0.85 CYP3A4 (0.76) CYP3A4CSF1RKDRGSK3AGSK3B
SCHEMBL1542952 0.85 CYP3A4 (0.76) CYP3A4CSF1RKDRGSK3AGSK3B
SCHEMBL1542386 0.84 CYP3A4 (0.64) CYP3A4TNFRSF1AEGFRERBB2CYP1A1
SCHEMBL1542383 0.84 CYP3A4 (0.64) CYP3A4TNFRSF1AEGFRERBB2CYP1A1
SCHEMBL1764330 0.84 CYP3A4 (0.74) CYP3A4TNFRSF1AEGFRERBB2CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885ROCK2 3473/4885CSF1R 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.